As expected, Monday, about a week after Merck received approval for Victrelis, Vertex Pharmaceuticals (VRTX) received approval for Incivek, its own Hep C drug. Incivek had slightly better response rates than Victrelis in clinical trials, but Merck has much more marketing might to put behind its drug. Hep C treatment is a multi billion dollar segment, and only time will tell how each drug does in capturing market share.
While on the subject of FDA approvals, Adam Feuerstein of TheStreet.com puts together a calendar of FDA decision dates and advisory panels. This has been recently updated, and is a great resource for keeping current. Here is the link. http://www.thestreet.com/story/11131722/1/biotech-calendar-2011-fda-drug-approvals.html puc=_mdb_html_pla10&cm_ven=EMAIL_mdb_html